Allogene CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial

 The FDA has cleared Allogene Therapeutics' IND application for ALLO-329, a novel dual-targeting CAR T cell therapy designed to treat multiple autoimmune diseases by simultaneously depleting both B cells and activated T cells. The Phase 1 RESOLUTION trial, set to begin in mid-2025, will evaluate this first-of-its-kind therapy in patients with lupus, inflammatory myopathies, and systemic sclerosis.

https://crisprmedicinenews.com/news/allogenes-dual-acting-car-t-candidate-allo-329-gets-fda-green-light-for-autoimmune-disease-trial/